# Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple Myeloma

> **NCT03520985** · PHASE2 · TERMINATED · sponsor: **Swiss Cancer Institute** · enrollment: 34 (actual)

## Conditions studied

- Refractory Multiple Myeloma

## Interventions

- **DRUG:** Pomalidomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT03520985
- **Lead sponsor:** Swiss Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-10-01
- **Primary completion:** 2021-02-03
- **Final completion:** 2021-02-03
- **Target enrollment:** 34 (ACTUAL)
- **Why stopped:** Feasibility (low patient accrual and financial reasons)
- **Last updated:** 2021-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03520985

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03520985, "Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03520985. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*